Clinical Trial Update: TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion [NA]

View source ↗

Summary

A completed clinical trial investigated transarterial chemoembolization (TACE) plus bevacizumab for hepatocellular carcinoma with portal vein invasion. The reco…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: The First Hospital of Hebei Medical University | Conditions: Hepatocellular Carcinoma (HCC) | NA | Status: COMPLETED